Korean Researchers Unveil Molecular Switch for Cancer Therapy

Breakthrough in Cancer Treatment: A New Approach to Reversing Cancer Cells
A groundbreaking development has emerged from South Korea, where a research team has created the first-ever "molecular reversion switch" technology. This innovative approach has the potential to transform cancer cells back into a near-normal state, offering a new dimension in the fight against cancer. Unlike traditional treatments that aim to destroy cancer cells, this method is expected to significantly reduce side effects and provide a more fundamental solution.
The National Cancer Center reported on the 9th that Professor Shin Dong-gwan from the Bioinformatics Research Division and Professor Cho Kwang-hyun from the Department of Bio and Brain Engineering at Korea Advanced Institute of Science and Technology (KAIST) have jointly developed a systems biology-based core technology called "REVERT." Systems biology combines IT technologies, mathematical modeling, and computer simulations with molecular and cellular biology experiments to analyze complex life phenomena.
Traditional vs. New Cancer Treatments
Traditional cancer treatments such as chemotherapy and radiation therapy have primarily focused on eliminating cancer cells. However, the newly developed treatment reverses the process, transforming cancer cells back into normal cells. This approach not only reduces side effects but also offers a more fundamental therapy. For many years, identifying which genes to regulate for such a reversal has been a significant challenge in academic research.
Identifying Key Genes and Enzymes
The research team began by analyzing single-cell gene data to identify the "critical transition state," which is the boundary between normal and cancer cells. This moment occurs just before cells fully become cancerous and presents an opportunity for intervention to revert them to a normal state. Based on this data, the team created a map of how genes within cells are interconnected and influence each other. They then conducted thousands of virtual experiments.
Through these experiments, the team identified two key genes, "YY1" and "MYC," as core switches in cancer cell transformation. These genes regulate cell growth and division, and suppressing them increases the likelihood of cells regaining normal properties. The team tracked the points co-regulated by these two genes and identified the "USP7" enzyme, which promotes tumor growth, as the final target.
Experimental Validation and Future Implications
The team administered a USP7 inhibitor to organ models derived from patients with colorectal cancer. The results showed a significant reduction in tumor growth and some restoration of characteristics found in normal colon tissue. This marks the first experimental validation of REVERT’s predictions and provides evidence that cancer cells can indeed be reverted to a normal state.
Professor Shin highlighted the significance of this discovery, stating, "While existing cancer treatments were like hammers smashing the cancer cell machine, REVERT is a precise tool that understands the machine’s circuitry, finds the faulty switch, and turns it back on. It holds significant meaning as it opens the possibility of a new treatment strategy that reverses cell fate."
Challenges and Next Steps
Despite the promising results, this study remains foundational at the cellular and organoid level. Clinical validation is necessary before this technology can be applied in patient treatment. The research team plans to expand the technology to various cancer types and explore new prevention and treatment strategies.
Funding and Publication
The research was supported by several key organizations, including the National Cancer Center’s Public Cancer Research Project, the Ministry of Science and ICT’s National Research Foundation Mid-Career Researcher and Basic Research Laboratory Projects, and the Ministry of Health and Welfare’s Korea Health Industry Development Institute Disease-Centered Translational Research Project. The findings were published in the January online edition of the international journal Advanced Science (IF 14.1).
Comments
Post a Comment